OTTAWA, Dec. 1, 2016 /CNW/ - A recent Health Canada safety review found that patients infected with both hepatitis B and hepatitis C viruses who are being treated for hepatitis C with direct-acting antivirals may experience a reactivation of their hepatitis B. Hepatitis B reactivation is the return of an active hepatitis B infection, which can lead to serious complications such as liver failure. As a result, Health Canada is working with manufacturers to
(July 13, 2016) – Health Canada has approved a drug being touted as a cure for hepatitis C, a disease believed to have infected hundreds of thousands of Canadians, many of whom are unaware they harbour the virus. The drug, sold under the brand name Epclusa, is a once-daily pill taken for 12 weeks that can rid the body of all six strains of hepatitis C, a blood-borne virus that can lead to severe liver damage and liver cancer if left untreated. “This ...
OTTAWA, Nov 10, 2015 /CNW/ - In response to new international safety information, Health Canada is advising Canadians that it is working with the manufacturer of Holkira Pak and Technivie to update drug labels (product monographs) to include new information regarding serious liver injury.Holkira Pak and Technivie are both used to treat chronic Hepatitis C viral infection that can lead to serious liver and health problems, including cirrhosis, liver cancer,
August 20, 2015: Today we received news that another upcoming drug, daclatasvir (Daklinza™) from Bristol-Myers Squibb, has received a Notice of Compliance from Health Canada. It is already being considered for coverage by British Columbia's Pharmacare, though it has not yet been approved. This drug is unique in its potential to mix and match with other drugs in order to treat a variety of genotypes, including hard-to-treat genotype 3 (combined with Gilead
What a Christmas Present! On December 23, 2014, Health Canada approved AbbVie's new interferon-free hepatitis C combo! HOLKIRA™ PAK (known in the USA as VIEKIRA™ PAK) has an overall 97% success rate for genotype 1 patients in research trials. All patients, even those with compensated cirrhosis, take it for only 12 weeks EXCEPT genotype 1a cirrhotic patients who have had a previous null response to pegylated interferon (pegIFN) and ribavirin, who must take
Canada's first "interferon-free combo" for hepatitis C, sofosbuvir+ledipasvir, now known by tradename HARVONI, was granted a "Notice of Compliance" (NOC) by Health Canada on Oct. 16, 2014. The NOC is basically an authorization to the combo's maker, Gilead Sciences, to market this treatment in the Canadian market. The pill, taken once a day for 8, 12, or 24 weeks (depending on condition of liver and previous treatment history), is only approved for use with
Sofosbuvir (trade name Sovaldi) has now been approved for use in Canada. There will still be many months before it is approved for coverage by your provincial Pharmacare plan. But meanwhile, if you are in great need of this drug but fear you cannot afford it, consider applying to Gilead Sciences compassionate care's Momentum Support Program™ or their Sovaldi Co-pay assistance program. See details in complete Gilead Sciences Press Release below. ### HEALTH
Simeprevir (trade name Galexos) has now been approved for use in Canada. It is a once-daily pill which is taken along with ribavirin and pegylated interferon alfa to treat hepatitis C genotype 1 in a "triple therapy." There will still be many months before it is approved for coverage by your provincial Pharmacare plan. See details in complete Janssen Inc. Press Release below. ### New Treatment for Hepatitis C Approved by Health Canada Priority Review Give